R-verapamil (CS 02) / ALK-Abello - LARVOL DELTA

Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. (PubMed, PLoS One) - "Hence, R-verapamil may be an optimal DM treatment as it is safe, improves glycemic control, and preserves β-cell function both as monotherapy and in combination with metformin or acarbose. R-Verapamil has potential for delaying or arresting DM progression and improving patients' quality of life."

Journal • Preclinical • Cardiovascular • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • IL6 • SSTR • SSTR2

CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - P2; N=201; Completed; Sponsor: Center Laboratories, Inc.; Recruiting ➔ Completed; Trial completion date: Mar 2021 ➔ Apr 2020; Trial primary completion date: Oct 2020 ➔ Apr 2020

Clinical • Combination therapy • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus